Novo Nordisk Secures Global Rights to China-Based Weight-Loss Drug in $2 Billion Deal

Danish pharmaceutical giant Novo Nordisk has secured global rights to develop, manufacture, and sell an experimental weight-loss drug from China’s United Laboratories International (TUL) in a deal worth up to $2 billion.

The agreement includes an upfront payment of $200 million, with additional milestone payments of up to $1.8 billion. The drug, UBT251, is a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors, which play a role in regulating appetite and metabolism. Early clinical trials in China showed promising results, with participants experiencing significant weight loss.

Under the deal, Novo Nordisk will handle global commercialization outside mainland China, Hong Kong, Macau, and Taiwan, where TUL retains its rights. The agreement positions Novo Nordisk to strengthen its presence in the growing obesity treatment market, where it already competes with blockbuster drugs like Wegovy and Ozempic.

This move comes amid rising competition from rival pharmaceutical companies, including Eli Lilly, which is advancing its own next-generation obesity treatments. Novo Nordisk’s stock saw a slight decline following the announcement, reflecting investor reactions to the high investment costs involved.